Shiroma Helio F, Farah Michel E, Takahashi Walter Y, Gomes Andre M V, Goldbaum Mauro, Rodrigues Eduardo Buchele
Department of Ophthalmology and Visual Science, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Division of Ophthalmology, Medical School, University of São Paulo, São Paulo, SP, Brazil.
Arq Bras Oftalmol. 2015 Jan-Feb;78(1):32-5. doi: 10.5935/0004-2749.20150009.
To evaluate and describe the precautions involved in the technique of intravitreal injection of antiangiogenic drugs adopted by the ophthalmologists who are members of the Brazilian Society of Retina and Vitreous (SBRV).
A questionnaire containing 22 questions related to precautions taken before, during, and after intravitreal injection was sent electronically to 920 members of SBRV between November 15, 2013 and April 31, 2014.
352 responses (38%) were obtained. There was a predominance of men (76%) from the southwest region of Brazil (51%). The professional experience varied between 6 and 15 years after medical specialization (50%). Most professionals (76%) performed an average of 1 to 10 intravitreal injections a week, and 88% of the procedures were performed in the operating room using povidone iodine (99%), sterile gloves, and blepharostat (94%). For inducing topical anesthesia, usage of anesthetic eye drops was the most used technique (65%). Ranibizumab (Lucentis®) was the most common drug (55%), and age-related macular degeneration (AMD) was the most treated disease (57%). Regarding the complications treated, 6% of the ophthalmologists had treated at least one case of retinal detachment, 20% had treated cases of endophthalmitis, 9% had treated cases of vitreous hemorrhage, and 12% had encountered cases of crystalline lens touch.
Intravitreal injection is a procedure routinely performed by retina specialists and has a low incidence of complications. Performing the procedure in the operating room using an aseptic technique was preferred by most of the respondents. Ranibizumab was the most used drug, and AMD was the most treated disease.
评估并描述巴西视网膜与玻璃体学会（SBRV）成员眼科医生采用的玻璃体内注射抗血管生成药物技术所涉及的预防措施。
2013年11月15日至2014年4月31日期间，一份包含22个与玻璃体内注射前、注射期间及注射后所采取预防措施相关问题的问卷，以电子方式发送给了920名SBRV成员。
共获得352份回复（38%）。受访者以来自巴西西南部地区的男性居多（76%，占51%）。医学专业毕业后的专业经验在6至15年之间的占多数（50%）。大多数专业人员（76%）每周平均进行1至10次玻璃体内注射，88%的操作在手术室进行，使用聚维酮碘（99%）、无菌手套和眼睑夹（94%）。在诱导局部麻醉方面，使用麻醉眼药水是最常用的技术（65%）。雷珠单抗（Lucentis®）是最常用的药物（55%），年龄相关性黄斑变性（AMD）是最常治疗的疾病（57%）。关于所治疗的并发症，6%的眼科医生至少治疗过1例视网膜脱离病例，20%治疗过眼内炎病例，9%治疗过玻璃体积血病例，12%遇到过晶状体接触病例。
玻璃体内注射是视网膜专科医生常规进行的操作，并发症发生率较低。大多数受访者更倾向于在手术室采用无菌技术进行该操作。雷珠单抗是最常用的药物，AMD是最常治疗的疾病。
